Biopharmaceuticals · global
US Cancer Drug Shortage Puts Indian Generics Back in the Spotlight
What appears to be an Indian pharmaceutical stock-market rally is in fact rooted in the fragility of the cancer treatment supply chain: when quality and capacity fall out of balance at the same time for inexpensive, mature, irreplaceable chemotherapy drugs, the pressure reaches the clinic before it reaches the capital market.
The most unsettling risk in cancer treatment does not necessarily come from the failure of new drugs. It can also come from being unable to obtain old ones. In recent years, repeated shortages in the United States of chemotherapy drugs such as cisplatin and carboplatin have once again placed large Indian generic drugmakers under the market’s microscope; NDTV Profit reported that companies including Zydus, Sun Pharma, and Dr. Reddy's have therefore become a focus for investors.
The medical significance of this stock-market signal is that it touches a group of basic medicines that are widely used clinically but relatively inexpensive. Cisplatin and carboplatin are not emerging targeted therapies, but core chemotherapy drugs in treatment regimens for multiple cancers. When supply tightens, physicians may have to delay treatment, adjust doses, or switch to alternatives that are not the most ideal options.
The pressure on US cancer centers had already shown signs. AP News previously cited a survey by the National Comprehensive Cancer Network as saying that among 27 cancer centers that responded, 25 reported a carboplatin shortage and 19 reported a cisplatin shortage, with nearly all surveyed centers affected by supply problems involving the two drugs. These figures were not a national census, but they clearly showed that the shortages had reached deep into major cancer care systems.
The shortages were not caused by a single event. The American Society of Health-System Pharmacists previously recorded that the cisplatin shortage was reported in January 2023, while carboplatin appeared in late March of the same year; AP News reported that a factory in India producing both drugs suspended production because of quality-related inspection concerns, which was one important backdrop to the supply pressure. Richard Pazdur, director of the FDA Oncology Center of Excellence, also previously told The Cancer Letter that the crisis reflected a dual failure of manufacturing capacity and market mechanisms, not just a problem with a single production line.
Drug shortages are difficult to resolve partly because these mature chemotherapy drugs have thin profit margins, limited suppliers, and manufacturing facilities that must meet strict quality requirements. Once a major production line shuts down because of inspection deficiencies, other manufacturers may not be able to fill the gap quickly; a cisplatin shortage may also drive up demand for carboplatin, putting the substitute drug itself under strain.
US regulators previously took measures including temporary imports of foreign-approved cisplatin, helping manufacturers increase supply, and requiring data to support extending the shelf life of some batches. These approaches can ease urgent pressure, but they cannot replace long-term investment: stable raw materials, predictable orders, sufficient redundant capacity, and regulatory transparency that can detect quality risks early are the core requirements for avoiding the next drug shortage.
The repricing of Indian pharmaceutical stocks may look like a business opportunity on the surface; for patients and health systems, the issue is more serious. If companies such as Zydus, Sun Pharma, and Dr. Reddy's are to play a larger role in the US cancer drug supply, the market will watch capacity, regulators will watch quality, and what matters most to clinicians is whether the drugs can reliably reach hospital wards when they are needed.